SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.86
+1.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 1.0M |
| Cost of Revenue | — | — | — | — | 100.0K |
| Gross Profit | — | — | — | — | 900.0K |
| Operating Expenses | |||||
| R&D Expense | 20.3M | 16.0M | 19.1M | 24.0M | 30.3M |
| SG&A Expense | 14.9M | 12.3M | 12.4M | 13.9M | 12.6M |
| General & Admin Expense | 14.9M | 12.3M | 12.4M | 13.9M | 12.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 35.2M | 28.3M | 31.5M | 37.9M | 42.9M |
| Cost and Expenses | 35.2M | 28.3M | 31.5M | 37.9M | 43.0M |
| Operating Income (EBIT) | (35.2M) | (28.3M) | (31.5M) | (37.9M) | (42.0M) |
| Non-Operating | |||||
| Interest Income | 2.8M | 1.4M | 632.0K | 525.0K | 317.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.8M | 1.4M | 632.0K | 525.0K | 317.0K |
| Other Non-Op Income/Expense | 2.8M | 1.4M | 632.0K | 529.0K | 649.0K |
| Non-Operating Income (excl Interest) | (2.8M) | (1.4M) | (632.0K) | (529.0K) | (10.0M) |
| EBT (Pre-Tax Income) | (32.5M) | (26.9M) | (30.9M) | (37.3M) | (41.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (32.5M) | (26.9M) | (30.9M) | (37.3M) | (41.3M) |
| Earnings from Cont. Ops | (32.5M) | (26.9M) | (30.9M) | (37.3M) | (41.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.5M) | (26.9M) | (30.9M) | (37.3M) | (41.3M) |
| Per Share | |||||
| Basic EPS | ($0.21) | ($0.25) | ($0.50) | ($1.34) | ($2.13) |
| Diluted EPS | ($0.21) | ($0.25) | ($0.50) | ($1.34) | ($2.13) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 189.2M | 109.1M | 61.2M | 27.8M | 19.4M |
| Diluted Shares Outstanding | 189.2M | 109.1M | 61.2M | 27.8M | 19.4M |
| Profitability Metrics | |||||
| EBITDA | (25.4M) | (26.9M) | 632.0K | 529.0K | (31.5M) |
| D&A | 7.1M | — | 31.5M | 37.9M | 457.0K |
| EBIT | (32.5M) | (26.9M) | (30.9M) | (37.3M) | (31.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026